Please assess the completion status of the following clinical trial:

Trial Title: Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females, 18-65 years old.~* Meets DSM-IV criteria for current diagnoses of cocaine and alcohol dependence, determined by the SCID.~* In the past 30 days, S used no less than $200-worth of cocaine and \>15 standard alcohol drinks (avg)/week with at least 1 day of 4 or more drinks, determined by the TLFB--adapted to collect daily cocaine use.~* Successful completion of alcohol detoxification, i.e.,~* 5 consecutive days of abstinence from cocaine and alcohol, via self-reports and negative urine toxicology screens.~* Lives a commutable distance to the TRC and agrees to follow-up visits.~* Understands and signs the consent.~Exclusion Criteria:~* Abstinent from cocaine or alcohol for 30 days prior to signing consent form. (S may have been institutionalized in the prior month and still be eligible if his/her cocaine and alcohol use that month met inclusion criteria.)~* Current DSM-IV diagnosis of any substance dependence other than cocaine, alcohol, nicotine, or cannabis determined by the SCID.~* Evidence of opiate use in the past 30 days, determined by self-report on the SCID or ASI, and/or by a urine drug screen that is positive for opiates at treatment entry.~* Current treatment with psychotropic medications (excluding short-term use of benzodiazepines for detoxification), including disulfiram.~* History of unstable or serious medical illness, including need for opioid analgesics.~* History of epilepsy or seizure disorder.~* Known severe physical or medical illnesses such as AIDS, active hepatitis, significant hepatocellular injury as evidenced by elevated bilirubin levels, or elevated levels over 4.5x normal of aspartate aminotransferase (AST), and serum glutamic-pyruvic transaminase (SGPT).~* Current severe psychiatric symptoms, e.g., psychosis, dementia, acute suicidal or homicidal ideation, mania or depression requiring antidepressant therapy, or which would make it unsafe for the patient to participate in the opinion of the primary investigators.~* Use of an investigational medication in the past 30 days.~* Female Ss who are pregnant, nursing, or not using a reliable method of contraception. \[Note: Criteria 4-10 will be assessed via the medical exam plus results from lab tests.\]

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Nal + BRENDA
- 2 (Type: PLACEBO_COMPARATOR): Placebo + BRENDA
- 3 (Type: EXPERIMENTAL): Nal + CBT
- 4 (Type: PLACEBO_COMPARATOR): Placebo + CBT

Based on this trial design, predict the completion outcome and termination type (if applicable).